Premier Medical Group - Multispeciality Practice in Clarksville, Tennessee

2 Apr

FDA approval of Rezdiffra by Madrigal


On March 14th Madrigal Pharmaceuticals announced the FDA approval of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis. For the full press release visit here.

Premier Clinical Research has participated in several of the Madrigal clinical studies helping to advance resmetirom. We would like to sincerely thank all of our patients that participated and continue to participate in these pivotal studies. It is due to the generosity and commitment of our patients that a prominent advancement such as this can occur and bring important treatment to many patients.

To learn more about Premier Clinical Research or see if a study is right for you please call 931-245-8444.

stylized Premier Medical logo